Functional and structural modifications of influenza antibodies during pregnancy

Highlights

Pregnancy resulted in structural and functional modulation of influenza antibodies.

Antibodies had differential binding capacity, Fc/Fab glycosylation, and function.

Antibody glycans directed toward low inflammation and efficient placental transfer.

Multivariate analysis of immune markers segregated pregnant and non-pregnant women.

Madeleine F. Jennewein, Martina Kosikova, Francesca J. Noelette, ..., Hang Xie, Galit Alter, Marcela F. Pasetti

hang.xie@fda.hhs.gov (H.X.)
galter@mgh.harvard.edu (G.A.)
mpasetti@som.umaryland.edu (M.F.P.)

Jennewein et al., iScience 25, 104088
April 15, 2022 ª 2022 The Authors.
https://doi.org/10.1016/j.isci.2022.104088
Functional and structural modifications of influenza antibodies during pregnancy

Madeleine F. Jennewein,1,4 Martina Kosikova,2,4 Francesca J. Noelette,1 Peter Radvak,2 Carolyn M. Boudreau,1 James D. Campbell,3 Wilbur H. Chen,3 Hang Xie,2,* Galit Alter,1,* and Marcela F. Pasetti3,4,5,*

SUMMARY
Pregnancy represents a unique tolerogenic immune state which may alter susceptibility to infection and vaccine response. Here, we characterized humoral immunity to seasonal influenza vaccine strains in pregnant and non-pregnant women. Although serological responses to influenza remained largely intact during late pregnancy, distinct modifications were observed. Pregnant women had reduced hemagglutinin subtype-1 (H1)-IgG, IgG1, IgG2, and IgG3, hemagglutination inhibition, and group 1 and 2 stem IgG titers. Intriguingly, H1-specific avidity and FcγR1 binding increased, and influenza antibodies had distinct Fc and Fab glycans characterized by increased di-galactosylation and di-sialylation. H1-specific Fc-functionality (i.e., monocyte phagocytosis and complement deposition) was moderately reduced in pregnancy. Multivariate antibody analysis revealed two distinct populations (pregnant vs. non-pregnant) segregated by H1 FcγR1 binding, H1-IgG levels, and Fab and Fc glycosylation. Our results demonstrated a structural and functional modulation of influenza humoral immunity during pregnancy that was antigen-specific and consistent with reduced inflammation and efficient placental transport.

INTRODUCTION
The immune system adapts in a precise and unique way during pregnancy to support fetal development and facilitate full-term delivery (Abu-Raya et al., 2020). These adaptations involve changes in cell phenotypes and frequencies (Th2 polarization, reduction of circulating NK and T cells, and reduction in the number of B cells) as well as modulation of cell function (i.e., cytokine production) (Kraus et al., 2010, 2012). In addition, antibodies produced during pregnancy display unique glycosylation patterns (Bondt et al., 2013, 2014; Einarsdottir et al., 2013). Collectively, these changes favor a non-inflammatory and tolerogenic environment (Alter et al., 2018; Lagattuta and Nigrovic, 2021). As a result, autoimmune conditions, such as rheumatoid arthritis, may transiently resolve during pregnancy (Forger and Forger, 2020). It has been proposed that a corollary of these alterations is increased maternal susceptibility to certain pathogens, which would also affect fetal health and development. For example, pregnant women are known to experience more severe influenza virus infection and are at higher risk of death, as evidenced during the 2009 H1N1 pandemic (Memoli et al., 2013; Kourtis et al., 2014). In the unfolding COVID-19 pandemic, symptomatic maternal infection posed a higher risk for unfavorable outcomes requiring hospitalization and invasive ventilation (Zambrano et al., 2020) and for fetal complications, including preterm birth, growth restriction, and miscarriage (Yee et al., 2020; Barrero-Castillero et al., 2020). These life-threatening health risks can be mitigated by interventions that strengthen prenatal immunity.

There is a long history of safe and effective immunization of pregnant women against tetanus and diphtheria (Rasmussen et al., 2014). In the past decade, the introduction of maternal acellular pertussis vaccine (ACIP, 2013) propitiously reduced infant hospitalizations and respiratory infections (Steinhoff et al., 2017; Amirthalingam et al., 2016). Seasonal influenza vaccination during pregnancy has been recommended to reduce the risk of infection and severity of disease of mothers and young infants (ACIP, 2013; Fiore et al., 2010; WHO, 2014). Several studies have demonstrated efficacy of this approach in reducing both maternal and infant hospitalization and illness (Thompson et al., 2019; Ohfuji et al., 2018; Regan et al., 2016).
Recognizing the value of this strategy to improve public health, a growing number of vaccine candidates intended to strengthen maternal-infant immunity through vaccination during pregnancy are advancing in the clinical pathway (Saso and Kampmann, 2020; Vojtek et al., 2018).

Conceivably, the profound physiological changes required to sustain pregnancy may also influence vaccine-induced immunity. Clinical studies of vaccination in pregnancy have focused primarily on the safety of these new interventions and their immunogenicity, through the analysis of serum antibody levels in mothers and their infants (Sperling et al., 2012; Schlaudecker et al., 2012; Ohfuji et al., 2018; Munoz et al., 2020). A few of these studies have examined maternal T cell responses (Huygen et al., 2015) and/or functional attributes of vaccine-induced antibodies (Jennewein et al., 2019). Some attention has been given to other factors influencing vaccine responses such as optimal gestational age to maximize infant seroprotection (Blanchard-Rohner et al., 2013; Eberhardt et al., 2016), and the effect of prior vaccination on maternal antibody levels (Christian et al., 2017).

The extent to which pregnancy per se influences vaccine-induced adaptive immunity and the implications of such changes for both maternal and infant health remain largely undefined. The wake of COVID-19 pandemic and rapid deployment of SARS-CoV-2 vaccines, created an opportunity to interrogate aspects in which pregnancy may impact vaccine-induced immunity (Shook et al., 2021). While knowledge is still evolving, some studies have found responses to be similar (Gray et al., 2021), while others observed reduced SARS-CoV-2 serum IgG and delayed antibody binding and effector functions in pregnant as compared to non-pregnant women (Bookstein Peretz et al., 2021; Atyeo et al., 2021). Recent results from a blood transcriptional profile analysis in pregnant women post influenza vaccination support the notion of pregnancy-intrinsic changes in interferon-stimulated and plasma cell gene expression that were associated with production of antibody (Giacomelli Cao et al., 2021).

Considering that antibodies are essential for protection against influenza, the goal of the present study was to examine the biophysical and functional properties of influenza-specific antibodies in pregnant and non-pregnant women, most of whom had received seasonal influenza vaccination. We tested the hypothesis that modifications of maternal antibody profiles during pregnancy would likely affect both canonical Fab- and extra-neutralizing Fc-mediated antibody functions, which are known to be key contributors to protective immunity (Boudreau and Alter, 2019). To this end, we conducted an in-depth characterization of antibodies to matched seasonal influenza vaccine strains in pregnant and non-pregnant women that included 1) serum antibody levels determined by hemagglutinin (HA) globular head and stem-specific IgG ELISA, hemagglutination inhibition (HAI), and microneutralization (MN); 2) HA-specific IgG avidity; 3) HA-specific IgG subclasses and Fc receptor binding by ELISA; 4) glycan profile of total and HA-specific IgG Fc and Fab molecules; and 5) Fc-mediated innate cell functions: antibody-dependent neutrophil phagocytosis (ADNP), antibody-dependent monocyte phagocytosis (ADCP), antibody-dependent complement deposition (ADCD), and antibody-dependent NK cell degranulation. Immunological outcomes in the two groups were compared using multivariate analysis. Distinct profiles of influenza-specific IgG Fab and Fc glycan profiles and function were identified between pregnant and non-pregnant women, with subtype-specific antibodies being differentially affected. Two well-defined segregated clusters were identified by aggregate multivariate data analysis. While influenza humoral immunity appeared to be largely unaffected during pregnancy, a deeper interrogation revealed distinct biophysical and functional antibody features. These results confirm previous reports of pregnancy-associated modulation of influenza immunity and provide evidence that support future-controlled clinical studies to inform the development of effective vaccines and guide immunization practices in this important population.

RESULTS

Pregnancy-associated differences in influenza-specific serum antibody levels

To understand pregnancy-associated modulation of humoral immunity, we conducted a comparative analysis of the magnitude, structural features, and functionality of antibodies to seasonal vaccine strains in pregnant and non-pregnant women, the majority of whom had received seasonal influenza immunization (Table S1). Women’s age and time of blood collection post vaccination were similar among participants. An un-biased multivariate principal components analysis (PCA) of the study population confirmed that there were no differences in antibody profiles based on vaccination status in either group (Figure S1). Immunity in the non-vaccinated participants is attributed to exposure to vaccine-matching strains circulating during...
The breadth of antibody responses in the two groups was determined through analysis of full-length HA- and HA-stem-specific serum IgG titers (Figures 1A and 1B) and canonical function of influenza antibodies: hemagglutinin inhibition (HAI) (C), microneutralization (MN) (D), and HA-specific IgG avidity (E) in pregnant and non-pregnant women. Data represent log transformed individual datapoints and geometric mean titers (bars) ± SD. ELISA, HAI, and MN titers were compared using one-tailed Mann-Whitney test. Difference in antibody avidity was evaluated using a two-tailed Mann-Whitney test *p < 0.05, **p < 0.01.

See also Table S1 and Figure S1.

Pregnant women had significantly lower IgG titers against H1 MI HA, as compared to the non-pregnant, while titers against H1 CA were unaffected (Figure 1A). Serum IgG directed to the conserved group 1
and group 2 HA 2009 stem regions were both substantially reduced in the pregnant women (Figure 1B).

Although both groups had similar HAI and MN titers for the contemporary vaccine strains H1 MI and H3 HK (Figures 1C and 1D), pregnant women did exhibit significantly reduced HAI titers against the original pandemic strain H1 CA (Figure 1C).

Intriguingly, the avidity of IgG against H1 CA HA was higher in the pregnant women as compared to the non-pregnant (Figure 1E). Likewise, a trend of higher IgG avidity against H1 MI HA was observed. Together, these results indicate that while serological responses to seasonal influenza remained largely unaffected, there were clear pregnancy-associated differences in magnitude, canonical functions, and strength of binding of influenza antibodies, which appeared to be antigen-specific.

Pregnancy influences HA IgG subclass and Fc receptor binding

To better understand the profile of influenza-specific antibodies elicited during pregnancy, we conducted a detailed class (IgG, IgA, and IgM) and subclass (IgG 1–4 and IgA 1–2) analysis of serum antibodies specific for full-length HA from H1 MI and H3 HK and their binding capacity to different Fc receptors using a multiplex Luminex assay (Figure 2). Consistent with the ELISA data described above (Figure 1A), pregnant women had significantly reduced levels of H1 MI HA-specific total IgG, IgG1, IgG2, and IgG3 as compared to non-pregnant women (Figures 2A and 2B). A trend of lower H3 HA-specific IgG and IgG1 was observed, while no differences were seen in either H1 MI or H3 HA-specific IgA1, IgA2, or IgM levels between the two groups (Figures 2A and 2B). Because of the different biophysical attributes and capacity of IgG subclasses to engage effector cells in extra-neutralizing effector function (Takai, 2002), the proportion (ratios) of IgG1:IgG4 and IgG3:IgG4 were calculated. Pregnant women had significantly lower ratios of IgG1:IgG4 and IgG3:IgG4 for both antigens, indicative of a higher proportion of IgG4 over the non-pregnant group (Figure 2C).

Clear differences were also seen in terms of HA-specific antibody binding to Fc receptors between the two groups (Figures 2D–2G). In contrast to the reduced HA-specific antibody binding patterns revealed by ELISA or Luminex assays, both H1 MI HA- and H3 HK HA-specific antibodies from pregnant women exhibited increased binding to FcγR1 as compared to the non-pregnant (Figure 2D). No differences in antibody binding capacity to other FcγR molecules were detected between two groups (Figures 2E–2G), except for reduced H1 HA-specific IgG binding to FcγR3 allotypic variant V in the pregnant group (Figure 2F).

Pregnancy alters antibody Fc and Fab N-glycosylation

To identify pregnancy-associated changes in influenza-specific antibody glycosylation, which can have a direct impact on antibody function (Alter et al., 2018; Jannenwein et al., 2019; Boudreau and Alter, 2019), we examined the Fc- and Fab-glycan composition of total and H1 MI- and H3 HK-specific serum IgG in both pregnant and non-pregnant women. For each of the samples, a total of 24 distinct glycan peaks were captured by capillary electrophoresis, and overall changes in the four differentially added sugars: galactose, sialic acid, bisecting n-acetyl glucosamine (GlcNAc), and fucose, were calculated for bulk (Figures 3A and 3B) and for HA-specific (Figures 3C–3F and 3G–3V) IgG for each group.

Compared to bulk IgG of non-pregnant women, the bulk Fc glycosylation profile of pregnant women revealed shifts toward increased fucosylation (F) and sialylation (S1 and S2) consistent with an anti-inflammatory phenotype (Figure 3A) (Anthony et al., 2008; Kaneko et al., 2006; Washburn et al., 2015, Shields et al., 2002, Shinkawa et al., 2003). On the other hand, pregnant women’s bulk Fab had fully fucosylated (F), galactosylated (G0 and G1), and bisected (B) glycans (Figures 3B and 3O–3V).

In contrast to the bulk molecules, Fc and Fab glycans of HA-specific antibodies were largely concordant and included digalactosylated (G2) structures with increased sialylation and reduced bisection.

**Figure 2. Pregnancy influences HA-specific IgG subclass and Fc receptor binding**

IgG, IgA, IgM, and IgG subclass and Fc receptor binding were assessed by Luminex. Dot plots depict individual levels for non-pregnant (NP, gray circles) and pregnant (P, blue circles) women. (A–G) (A) Isotypes. (B) IgG subclasses. (C) IgG1/IgG4 and IgG3/IgG4 ratios. (D) Class 1 Fc receptor. (E) Class 2 Fc receptors. (F) Class 3 Fc receptors. (G) Neonatal Fc receptor. Lines at mean ± SD. Groups were compared by Mann-Whitney test, and asterisks represent differences between pregnant and non-pregnant individuals. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Figures 3C–3F and 3G–3V) in the pregnant group, whereas agalactosylated, monosialylated, and bisected structures were predominant in the non-pregnant group. Taken together, these results point to a distinct Fab and Fc glycan profile of antigen-specific antibodies produced during pregnancy consistent with distinct capacity for antigen-recognition (Fab) and Fc-mediated extra-neutralizing antibody function and finely modulated inflammatory properties.

To explore possible associations between Fab and Fc glycosylation, we performed correlation analyses between glycans of HA-specific antibodies in both groups (Figures 3W and 3X). Significant associations between specific glycan types were detected (Figures 3W and 3X), which suggest coordinated glycosylation of both Fab and Fc molecules. This was particularly evident in the non-pregnant group.

Antigen-specific extra-neutralizing antibody functions are selectively affected by pregnancy

Given the observed differences in magnitude and glycan composition of HA-specific antibodies during pregnancy, we next investigated their Fc-mediated effector functions. Responses were measured independently for the two vaccine strains (H1 MI and H3 HK). Monocyte phagocytosis (ADCP) and complement deposition (ADCD) activity of H1 HA-specific antibodies were significantly lower in pregnant women as compared to the non-pregnant women (Figures 4B and 4C). Intriguingly, no differences were seen in neutrophil phagocytosis (ADNP) and NK degranulation (Figures 4A, 4D, and 4E). Both H1 HA- and H3 HA-specific antibodies in the pregnant group exhibited reduced cytotoxicity (ADCC) although it did not reach statistical significance (Figure 4F). Overall, a consistent trend toward reduced antibody functionality across FcR-dependent functions was observed in the pregnant women. The predominant changes on H1 HA-specific antibody function further support pregnancy-associated impact on antigen-specific humoral immunity.

Multivariate signatures of antibodies during pregnancy

To determine whether pregnant and non-pregnant could be distinguished based on distinct features of influenza humoral immunity, we first examined the data using PCA as an unbiased multivariate method (Figure S1). Pregnant and non-pregnant antibody features segregated within the PCA along PC1, with a 12% variance between the two populations. Given the differences seen in the PCA, and to further dissect the differences between antibodies in the two groups, a least absolute shrinkage and selection operator and LASSO Partial Least Squares Discriminant Analysis (LASSO-PLSDAs) was conducted. This multivariate computational modeling technique allowed the determination of features that contributed most strongly to variance between the two groups, and these predictors were then visualized on the PLSDA plot. This analysis included all the influenza-specific variables assessed (serum IgG, HAI and MN titers, antibody subtypes, Fc receptor binding, glycosylation, and Fc-effector functions), 79 in total. Readouts from pregnant and non-pregnant groups were separated and orthogonalized along LV1 (Figure 5A). The antibody features that contributed to a separation between groups were then ranked by their importance (Figure 5B). The top predictor was H1 HA-specific antibody binding to FcyR1, which was greatly enriched in pregnant women. Another predictor was the lower H1 HA-specific IgG titer in the pregnant group. The remaining predictors were mainly Fc and Fab glycan residues. The groups segregated in antigen-specific antibody galactosylation profiles; anti-inflammatory H3 HA Fc G1B and H1 HA Fc G2S2F glycans were preeminent in pregnant women whereas inflammatory H1 HA Fc-G1F/G1FB and H1 HA Fab-G0 dominated in the non-pregnant group. Thus, Fc glycosylation and Fc receptor binding were the primary driving forces in determining the model. Most of the parameters downselected with VIP scores were H1MI HA-specific even though H1 MI, H1 CA, and H3 HK HA-specific readouts were included in the model, reinforcing the notion of antigen dependency of pregnancy-induced antibody changes.
DISCUSSION

Seasonal influenza vaccination during pregnancy is recommended by the Advisory Committee on Immunization Practices (Grohskopf et al., 2020) and the ACOG, (2018). The heightened susceptibility of pregnant women to severe influenza infection during the 2009 H1N1 pandemic (Siston et al., 2010; Jamieison et al., 2009; Louie et al., 2010) brought attention to the importance of vaccination for protection of both mothers and infants. The COVID-19 pandemic confirmed the urgent need for strategies and public health preparedness to protect pregnant women and their newborns (Shook et al., 2021). There has been renewed interest, in recent years, in expanding routine maternal immunization against other pathogens (e.g., respiratory syncytial virus, cytomegalovirus, group B streptococcus, etc.) that are important causes of neonatal and infant death. This approach, however, faces unique challenges. Fine-tuned regulatory mechanisms are deployed during pregnancy to balance the tolerogenic environment necessary to avoid unhealthy reactions to paternal antigens with the need to engage robust adaptive immunity against microbial threats (Mor and Cardenas, 2010; Schumacher et al., 2014). Profound changes in humoral immunity occur during gestation, which include decreased number of peripheral B cells (Watanabe et al., 1997; Faucette et al., 2015), and increased IL-10-secreting regulatory B cells (Rolle et al., 2013). These changes are also expected to impact vaccine-induced immunity.

In this study, we report, for the first time, distinct binding and functional features of antibodies specific for seasonal influenza vaccine strains, produced during pregnancy. Although overall humoral influenza immunity appeared to be largely intact, there were clear differences between the pregnant and non-pregnant groups. Among the most notable is the overt reduction in total IgG and IgG subclasses specific for the H1 MI vaccine strain. HAI titers against H1 CA—the original 2009 H1N1 pandemic strain—were also reduced below seroprotective levels. In contrast, HAI and MN titers to seasonal vaccine strains were largely...
unaffected, which suggests that canonical antibody activity (i.e. virus neutralization and cell-adhesion inhibition) was preserved during pregnancy, even though Fc-mediated extra-neutralizing function was greatly compromised, as discussed below.

Changes in antibody levels affected primarily those against H1 HA but not those against H3 HA. This could be due to immune imprinting, because H1 CA-like viruses have continued to circulate globally since the 2009 H1N1 pandemic (H1 MI is an antigenically drifted H1 CA-like virus) while the subclade of predominant H3 virus has changed almost every other year (WHO, 2022; Allen and Ross, 2018). In response to the antigenically drifted H3 virus, immune memory is recalled, favoring the production of antibodies that recognize common epitopes from previous infections or vaccinations, over de novo antibody responses to unseen epitopes. The history of prior influenza exposure of these women and preexisting immunity are not known and could have influenced the responses detected (Kosikova et al., 2018). Others have reported reduced HA-specific IgG and IgG subclass responses, as well as HAI titers to seasonal influenza vaccines during pregnancy (Schlaudecker et al., 2012, 2018; Bischoff et al., 2013). These studies examined pre-vaccination samples and yet found similar reductions in post-vaccine immunity during pregnancy regardless of basal antibody titers. Additionally, Schlaudecker et al. (2018) reported a decline in response to influenza vaccination as pregnancy progress, which suggests that the antibody modulations we and others have observed are intrinsic to the gestational period.

Figure 5. Multivariate signatures of antibodies produced during pregnancy
Computational analysis was used to distinguish features enriched in pregnancy.
(A) LASSO Partial Least Squares Discriminant Analysis (LASSO-PLSDA) of influenza-specific antibody features between pregnant and non-pregnant women orthogonalized along latent variable 1 (LV1). LV1 explains 42.5% of the variance along the X axis while LV2 explained 17.1% of the variance.
(B) The Variable Importance in Projection (VIP) scores for the PLSDA indicate the prime factors driving the differences between pregnant and non-pregnant women. Factors pointing toward the left are enriched in non-pregnant samples, while those pointing right are enriched in pregnant samples. Bar color and length corresponds to relative importance. Antibody features are colored by category.
Pregnant women had significantly lower IgG1/IgG4 and IgG3/IgG4 ratios in response to both H1 and H3 vaccine strains, which is consistent with a Th2-type shift of humoral immunity during gestation. IgG1 and IgG3 are the main subclasses produced in response to viral antigens (Hjelholt et al., 2013), while IgG4 appears to be less functional, with lower affinity for Fc receptors (Jung et al., 2006; Bruhns et al., 2009; Vidarsson et al., 2014), and usually associated with allergic responses (Vidarsson et al., 2014). The increased proportion of IgG4 during pregnancy is consistent with impaired Fc-mediated cellular function. It has been proposed that antibody-dependent cellular function is less affected by antigenic drift and potentially provides influenza heterosubtypic protection (Von Holle and Moody, 2019). Thus, suboptimal cell engagement during pregnancy could reduce vaccine effectiveness and cross protective immunity. Further studies are warranted to understand influenza humoral immunity beyond traditional markers and in particular determinants of extra-neutralizing antibody function and its contribution to protection particularly in high-risk populations.

In addition to lower IgG response to the H1 vaccine strain, pregnant women had reduced IgG titers against highly conserved group 1 and group 2 HA stem regions. This observation is new and suggests that production of stem-specific antibodies during pregnancy might be impaired and that these antibodies could be limited in their capacity to recognize emerging virus variants. Additional investigations to understand HA stem-specific immunity in this group is important as stem antibodies are hypothesized to confer broad cross-protection (Wu and Wilson, 2017) and are candidate antigens for sought after universal flu vaccines (Sautto et al., 2018).

Intriguingly, we found that H1 HA-specific IgG in pregnant women had higher avidity compared to those from non-pregnant women. In addition, HA-specific antibodies produced during pregnancy had increased capacity to bind FcγR1. FcγR1 is an activating receptor expressed in monocyte/macrophages and dendritic cells, with high affinity for human monomeric IgG, particularly IgG1 (Stewart et al., 2014; Bruhns et al., 2009). On the other hand, H1 HA-specific IgG from pregnant women had reduced binding capacity to FcγRIIa-V, a high affinity allotype receptor expressed in monocytes/macrophages and NK cells. The enhanced capacity of pregnancy-distinct antibodies to bind cognate antigens and to selectively engage in innate cell function via Fc-interaction may represent compensatory mechanisms to maximize response yet avoid harmful effects.

Another innovative aspect of our study was the analysis of extra-neutralizing FcR-mediated antibody functions in pregnant women. H1-specific ADCC, ADCD, and ADCC were reduced in this group, and this observation is consistent with reduced levels of H1 IgG, and in particular IgG1, which triggers these processes efficiently by engaging FcγRI (Gunn and Alter, 2016). The reduced capacity of H1 HA antibodies to bind to FcγRIII-V might have also contributed to this outcome. IgG1 has been implicated in activation of complement in the context of influenza infection; hence, reduced IgG1 in this group is consistent with lower C3 deposition.

Unlike FcR-mediated monocyte/macrophage uptake, neutrophil phagocytic activity and NK degranulation both appeared unaffected during pregnancy. Neutrophil phagocytosis can be activated by different and additional signals such as IgG2 interaction with FcyRIIa and IgA with FcαRI (Gunn and Alter, 2016). NK degranulation was maintained in the pregnant group despite their antibodies exhibiting lower binding affinity for FcγRIIa (the cellular receptor that mediates NK degranulation). These observations further support the idea of compensatory mechanisms of the humoral immune system to offset pregnancy-intrinsic changes and maintain a healthy state.

Vastly different glycosylation of total and influenza-specific antibodies was observed in pregnant women compared to non-pregnant controls. The total Fc glycan profile in pregnant women, which included fucosylation and sialylation, was oriented toward reduced inflammation (Alter et al., 2018; Lagattuta and Nigrovic, 2021). In contrast, the total Fab glycans, which involved increased fucosylation, agalactosylation, and bisection, had been associated with increased inflammation (Alter et al., 2018; Lagattuta and Nigrovic, 2021). Non-inflammatory Fc galactosylation and sialylation as well as Fab N-acetylgalactosamine bisection of bulk antibodies during pregnancy have been reported elsewhere (Sondt et al., 2014, 2016; Jansen et al., 2016; Ruhaak et al., 2014; Van De Geijn et al., 2009; Selman et al., 2012). Surprisingly, the Fc and Fab glycan profile of HA-specific antibodies were largely concordant within each group and included digalactosylated (G2) structures with increased sialylation and reduced bisection in the pregnant group, whereas
agalactosylated, monosialylated, and bisected structures were predominant in the non-pregnant group. The association patterns remained broadly unchanged in the two groups, which indicate a coordinated global regulation of Fc and Fab glycosylation. However, other factors governing production of Fab and Fc glycans may reduce the overall level of coordination to reflect the putative greater level of Fab glycosylation during pregnancy (Van De Bovenkamp et al., 2016).

Two distinct populations emerged in the PLSDA analysis, with Fc and Fab glycosylation being primary discriminatory elements; the clear separation of the two groups confirms the robustness of the data. The similarity in Fc and Fab glycosylation for the influenza-specific antibodies suggests some level of coordination of post-translational modifications that differs according to the B cell population. This is the first demonstration of Fab and Fc glycosylation of vaccine-specific antibodies consistent with non-inflammatory activity in pregnant women and different from the more inflammatory pattern in the non-pregnant group. Despite the disparity in antibody glycosylation, all the relevant Fc-mediated influenza-specific cellular functions were detected in the pregnant group.

We have previously shown that digalactosylated antibodies involved in NK degranulation were enriched in cord blood; these digalactosylated antibodies preferentially bind to the neonatal Fc receptor (FcRn), which transits antibodies across the placenta (Jennewein et al., 2019; Martinez et al., 2019). Digalactosylated antibodies are reportedly more effective at facilitating NK degranulation, a function the neonatal immune system is better equipped to deploy as opposed to phagocytosis or other extra-neutralizing functions (Jennewein et al., 2019). For the mother, digalactosylation of antibodies during gestation may reflect another compensatory mechanism that maintains ADNP unaltered when other cellular functions may be reduced. Likewise, sialylation has been exploited in immunoglobulin therapy to endow anti-inflammatory benefits (Anthony et al., 2008; Pagan et al., 2018; Bruckner et al., 2017). Here, enhanced Fc-sialylation during pregnancy may contribute to dampened antibody-mediated inflammation consistent with the tolerizing state of pregnancy (Pagan et al., 2018).

Together, the shifts observed in influenza-specific antibodies during pregnancy are consistent with reduced inflammation, more efficient Fc receptor engagement to maintain antiviral function (as the magnitude of antibody available might be reduced), enhancement of placental transfer, reduction in antibody catabolism, and enrichment of antibodies that are more efficient for the newborn. The origin, regulation, evolution, and duration of these pregnancy-associated antibody changes remain to be investigated.

Rather than broad immune suppression during pregnancy (reviewed in Memoli et al., 2013), our data suggest that humoral immunity is selectively modulated by changes in antibody levels, avidity, FcR binding capacity, glycosylation patterns, and innate cellular functions. Our results also argue against universally compromised humoral immunity and in favor of discrete, antigen-dependent modifications. Whether these changes are transient (restricted to pregnancy) or more durable remain to be determined. Clinical studies to investigate modulation of influenza immunity in pregnant women longitudinally and beyond delivery are needed to corroborate these findings, and to deepen our understanding of this physiological process and the mechanisms involved.

The overall antibody modulations we have observed may not be restricted to influenza but could impact other vaccine antigens. Lower pertussis toxin (PT) serum IgG responses have been reported post vaccination in pregnant women that received the licensed tetanus-diphtheria-pertussis (TdaP) vaccine in the third trimester as compared to non-pregnant women (Peer et al., 2021). Similarly, a reduction of PT-specific IgG in TdaP-vaccinated pregnant women compared with non-pregnant had been reported earlier (Fortner et al., 2018).

Limitations of the study

Our study is limited by a small sample size, race/ethnicity distribution, and the retrospective analysis of immune responses to influenza seasonal vaccine strains. Nonetheless, it still provides a valuable snapshot of vaccine-specific immunity in the pregnant population.

Maternal infections place women and their infants at high risk. Understanding the nature and extent of pregnancy-associated changes in antibody production, post-translational modifications and function, as well as how these processes affect vaccine responses will inform vaccine design, immunization strategies,
and the development of much needed preventive and therapeutic strategies, particularly those for use in
emergency situations, to improve maternal and infant health.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODELS AND SUBJECT DETAILS**
  - Cell lines
  - Viruses
  - Recombinant proteins
- **METHOD DETAILS**
  - Anti-HA ELISA and avidity
  - Hemagglutination inhibition (HAI)
  - Complement deposition
  - NK cell activation
  - Microneutralization (MN)
  - Phagocytosis
  - Cellular cytotoxicity
  - Antibody subclass and FcR binding
  - Glycosylation analysis
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2022.104088.

ACKNOWLEDGMENTS
H.X. was supported by the FDA Office of Women's Health, award #20-01-0010. This work was supported in part by NIH/NIAID U19AI145825 to H.X. and M.F.P. (Project 1) and G.A. (Core 1).

AUTHOR CONTRIBUTIONS
Conceptualization, M.F.J., H.X., G.A., and M.F.P.; Clinical samples: M.F.P, W.H.C., and J.D.C. Investigation; M.F.J., M.K., F.J.N., P.R., and C.M.B.; Resources, H.X., G.A., and M.F.P.; Writing-Original draft, M.F.J, H.X., G.A., and M.F.P.; Writing-review and editing, J.D.C and W.H.C.; Supervision, H.X., G.A., and M.F.P.

DECLARATION OF INTERESTS
C.B. is an employee and equity holder of Leyden Labs, a company developing pandemic prevention therapeutics. G.A. is a founder and equity holder of Seromyx Systems, a company developing a platform technology that describes the antibody immune response. G.A. is an employee and equity holder of Leyden Labs, a company developing pandemic prevention therapeutics. G.A.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.

INCLUSION AND DIVERSITY
One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community.

Received: May 18, 2021
Revised: October 14, 2021
Accepted: March 14, 2022
Published: April 15, 2022
REFERENCES

Ackerman, M.E., Molch, B., Wyatt, R.T., Dougast, A.S., McAndrew, E., Tsoukas, S., Jost, S., Berger, C.T., Sciaranghella, G., Liu, Q., Irvine, D.J., Burton, D.R., and Alter, G. (2011). A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8–19.

ACOG (2018). Committee opinion no. 732. Influenza Vaccination During Pregnancy. Obstet. Gynecol. 131 (4), e109–e114.

WHO (2014). Safety of immunization during pregnancy: a review of the evidence. Global Advisory Committee on Vaccine Safety. (World Health Organization). https://apps.who.int/iris/handle/10665/340577.

WHO (2017). Recommended Composition of Influenza Virus Vaccines for Use in the 2017–2018 Northern Hemisphere Influenza Season (World Health Organization). https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2017-2018-northern-hemisphere-influenza-season.

Abu-Raya, B., Michalski, C., Sadarangani, M., and Lavoie, P.M. (2020). Maternal Immunological Adaptation During Normal Pregnancy. Front. Immunol. 11, 575197.

ACIP (2013). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women. 07 ed. MMWR Morb. Mortal. Wkly Rep. 60, 1424–1426.

Allen, J.D., and Ross, T.M. (2018). H3N2 influenza viruses in humans: viral mechanisms, evolution, and evaluation. Hum. Vaccin. Immunother. 14, 1840–1847.

Alter, G., Ottenhoff, T.H.M., and Joosten, S.A. (2020). COVID-19: neonatal activity with a recombinant IgG Fc. Science 366, 915–927. https://doi.org/10.1126/science.abc8631.

Akbarnia, A., Boyko, A., Kowalewski, A., Leclercq, P., and Kolesnikov, G. (2020). Sustained Effectiveness of the Maternal Influenza Virus Vaccines for Use in the 2017-2018 Northern Hemisphere Influenza Season (World Health Organization). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358310/

REFERENCES

ACIP (2013). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women. 07 ed. MMWR Morb. Mortal. Wkly Rep. 60, 1424–1426.

Allen, J.D., and Ross, T.M. (2018). H3N2 influenza viruses in humans: viral mechanisms, evolution, and evaluation. Hum. Vaccin. Immunother. 14, 1840–1847.

Alter, G., Ottenhoff, T.H.M., and Joosten, S.A. (2020). COVID-19: neonatal activity with a recombinant IgG Fc. Science 366, 915–927. https://doi.org/10.1126/science.abc8631.

Akbarnia, A., Boyko, A., Kowalewski, A., Leclercq, P., and Kolesnikov, G. (2020). Sustained Effectiveness of the Maternal Influenza Virus Vaccines for Use in the 2017-2018 Northern Hemisphere Influenza Season (World Health Organization). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358310/
Atmar, R.L. (2020). Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2020-21 influenza season. MMWR Recomm. Rep. 69, 1–24.

Gunn, B.M., and Alter, G. (2016). Modulating antibody functionality in infectious disease and vaccination. Trends Mol. Med. 22, 969–982.

Hjelholt, A., Christiansen, G., Sorensen, U.S., and Birkelund, S. (2013). IgG subclass profiles in normal human sera of antibodies specific to five kinds of microbial antigens. Pathog. Dis. 67, 206–213.

Huygen, K., Cabore, R.N., Maertens, K., Van Damme, P., and Leuridan, E. (2015). Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and nonpregnant women. Vaccine 33, 4117–4123.

Jacobsen, H., Rajendran, M., Choi, A., Sjursen, H., Brahthaid, K.A., Cox, R.J., Palese, P., Krammer, F., and Nachbagauer, R. (2017). Influenza virus hemagglutinin stalk-specific antibodies in human serum are a surrogate marker for in vivo hemagglutinin stalk-specific antibodies in human.

Kraus, T.A., Speerling, R.S., Kellerman, L., Lo, Y., Wal lenstein, S., Escribese, M.M., Garrido, J.L., Singh, T., Louboue, M., and Moran, T.M. (2012). Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J. Clin. Immunol. 32, 300–311.

Kraus, T.A., Speerling, R.S., Engle, S.M., Lo, Y., Kellerman, L., Singh, T., Louboue, M., Ge, Y., Garrido, J.L., Rodriguez-Garcia, M., and Moran, T.M. (2010). Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am. J. Reprod. Immunol. 64, 411–426.

Kraus, T.A., Engel, S.M., Speerling, R.S., Kellerman, L., Lo, Y., Wal lenstein, S., Escribese, M.M., Garrido, J.L., Singh, T., Louboue, M., and Moran, T.M. (2012). Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J. Clin. Immunol. 32, 300–311.

Kraus, T.A., Speerling, R.S., Engle, S.M., Lo, Y., Kellerman, L., Singh, T., Louboue, M., Ge, Y., Garrido, J.L., Rodriguez-Garcia, M., and Moran, T.M. (2010). Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am. J. Reprod. Immunol. 64, 411–426.

Kraus, T.A., Engel, S.M., Speerling, R.S., Kellerman, L., Lo, Y., Wal lenstein, S., Escribese, M.M., Garrido, J.L., Singh, T., Louboue, M., and Moran, T.M. (2012). Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J. Clin. Immunol. 32, 300–311.

Kraus, T.A., Speerling, R.S., Engle, S.M., Lo, Y., Kellerman, L., Singh, T., Louboue, M., Ge, Y., Garrido, J.L., Rodriguez-Garcia, M., and Moran, T.M. (2010). Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am. J. Reprod. Immunol. 64, 411–426.

Kraus, T.A., Engel, S.M., Speerling, R.S., Kellerman, L., Lo, Y., Wal lenstein, S., Escribese, M.M., Garrido, J.L., Singh, T., Louboue, M., and Moran, T.M. (2012). Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J. Clin. Immunol. 32, 300–311.

Kraus, T.A., Speerling, R.S., Engle, S.M., Lo, Y., Kellerman, L., Singh, T., Louboue, M., Ge, Y., Garrido, J.L., Rodriguez-Garcia, M., and Moran, T.M. (2010). Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am. J. Reprod. Immunol. 64, 411–426.

Kraus, T.A., Engel, S.M., Speerling, R.S., Kellerman, L., Lo, Y., Wal lenstein, S., Escribese, M.M., Garrido, J.L., Singh, T., Louboue, M., and Moran, T.M. (2012). Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J. Clin. Immunol. 32, 300–311.

Kraus, T.A., Speerling, R.S., Engle, S.M., Lo, Y., Kellerman, L., Singh, T., Louboue, M., Ge, Y., Garrido, J.L., Rodriguez-Garcia, M., and Moran, T.M. (2010). Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am. J. Reprod. Immunol. 64, 411–426.

Kraus, T.A., Engel, S.M., Speerling, R.S., Kellerman, L., Lo, Y., Wal lenstein, S., Escribese, M.M., Garrido, J.L., Singh, T., Louboue, M., and Moran, T.M. (2012). Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J. Clin. Immunol. 32, 300–311.

Kraus, T.A., Speerling, R.S., Engle, S.M., Lo, Y., Kellerman, L., Singh, T., Louboue, M., Ge, Y., Garrido, J.L., Rodriguez-Garcia, M., and Moran, T.M. (2010). Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am. J. Reprod. Immunol. 64, 411–426.

Kraus, T.A., Engel, S.M., Speerling, R.S., Kellerman, L., Lo, Y., Wal lenstein, S., Escribese, M.M., Garrido, J.L., Singh, T., Louboue, M., and Moran, T.M. (2012). Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J. Clin. Immunol. 32, 300–311.

Kraus, T.A., Speerling, R.S., Engle, S.M., Lo, Y., Kellerman, L., Singh, T., Louboue, M., Ge, Y., Garrido, J.L., Rodriguez-Garcia, M., and Moran, T.M. (2010). Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am. J. Reprod. Immunol. 64, 411–426.

Kraus, T.A., Engel, S.M., Speerling, R.S., Kellerman, L., Lo, Y., Wal lenstein, S., Escribese, M.M., Garrido, J.L., Singh, T., Louboue, M., and Moran, T.M. (2012). Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J. Clin. Immunol. 32, 300–311.

Kraus, T.A., Speerling, R.S., Engle, S.M., Lo, Y., Kellerman, L., Singh, T., Louboue, M., Ge, Y., Garrido, J.L., Rodriguez-Garcia, M., and Moran, T.M. (2010). Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am. J. Reprod. Immunol. 64, 411–426.
presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278: 3466–3473.

Shook, L.L., Fallah, P.N., Silberman, J.N., and Eddow, A.G. (2021). Covid-19 vaccination in pregnancy and lactation: current Research and gaps in understanding. Front. Cell Infect. Microbiol. 11, 735394.

Siston, A.M., Rasmussen, S.A., Honein, M.A., Fry, A.M., Seib, K., Callaghan, W.M., Louie, J., Doyle, T.J., Crockett, M., Lynfield, R., et al. (2010). Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 303, 1517–1525.

Sperling, R.S., Engel, S.M., Wallenstein, S., Kraus, T.A., Garrido, J., Singh, T., Kelleman, L, and Moran, T.M. (2012). Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum. Obstet. Gynecol. 119, 631–639.

Steinhoff, M.C., Katz, J., Englund, J.A., Khattry, S.K., Shrestha, L., Kuppers, J., Stewart, L., Mullany, L.C., Chu, H.Y., LeClerq, S.C., Kozuki, N., et al. (2017). Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infect Dis 17 (9), 981–989.

Stevens, J., Corper, A.L., Basler, C.F., Taubenberger, J.K., Palese, P., and Wilson, I.A. (2004). Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303, 1866–1870.

Stewart, R., Hammond, S.A., Oberst, M., and Wilkinson, R.W. (2014). The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. J. Immunother. Cancer 2, 29.

Takai, T. (2002). Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2, 580–592.

Thompson, M.G., Kwong, J.C., Regan, A.K., Katz, M.A., Drews, S.J., Azizz-BAumgartner, E., Klein, N.P., Chung, H., Effler, P.V., Feldman, B.S., et al. (2019). Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010-2016. Clin. Infect. Dis. 68, 1444–1453.

Van De Bovenkamp, F.S., Hafkenscheid, L., Rispens, T., and Rombouts, Y. (2016). The emerging importance of IgG Fab glycosylation in immunity. J. Immunol. 196, 1435–1441.

Van De Geijn, F.E., Wuhrer, M., Selman, M.H., Willemsen, S.P., De Man, Y.A., Deelder, A.M., Hazes, J.M., and Dohain, R.J. (2009). Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res. Ther. 11, R193.

Vidarsson, G., Dekkers, G., and Rispens, T. (2014). IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5, 520.

Vojtek, I., Dieussaert, I., Doherty, T.M., Franck, V., Hanssens, L., Miller, J., Bekkat-Berkani, R., Kandel, W., Prado-Cohrs, D., and Vyse, A. (2018). Maternal immunization: where are we now and how to move forward? Ann. Med. 50, 193–208.

Von Holle, T.A., and Moody, M.A. (2019). Influenza and antibody-dependent cellular cytotoxicity. Front. Immunol. 10, 1457.

Watanabe, M., Iwatai, Y., Kaneda, T., Hidaka, Y., Mitsuda, N., Mormoto, Y., and Amino, N. (1997). Changes in T, B, and NK lymphocyte subsets during and after normal pregnancy. Am. J. Reprod. Immunol. 37, 368–377.

WHO Global Influenza Programme. Recommendations for influenza vaccine composition. https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations.

Wu, N.C., and Wilson, I.A. (2017). A perspective on the structural and functional constraints for immune evasion: insights from influenza virus. J. Mol. Biol. 429, 2694–2709.

Xie, H., Jing, X., Li, X., Lin, Z., Plant, E., Zouev, O., Yang, H., and Ye, Z. (2011). Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS One 6, e16650.

Xie, H., Wan, X.F., Ye, Z., Plant, E.P., Zhao, Y., Xu, Y., Li, X., Finch, C., Zhao, N., Kawano, T., et al. (2015). H3N2 mismatch of 2014-15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps. Sci. Rep. 5, 15279.

Yee, J., Kim, W., Han, J.M., Yoon, H.Y., Lee, N., Lee, K.E., and Gwak, H.S. (2020). Clinical manifestations and perinatal outcomes of pregnant women with COVID-19: a systematic review and meta-analysis. Sci. Rep. 10, 18126.
## STAR★METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| horseradish peroxidase-labeled goat-anti-human IgG | Invitrogen | # A18805; RRID:AB_2535582 |
| FITC Goat IgG anti-C3 | MP Biomedicals | CAT # 855385 |
| CD107a PE-Cy5 Mouse Anti-Human | BD Biosciences | CAT#555802; clone: H4A3; RRID:AB_396136 |
| Alexa Fluor® 700 Mouse Anti-Human CD3 | BD Biosciences | CAT#557943; clone: UCHT1; RRID:AB_396952 |
| CD56 PE-Cy7 Mouse Anti-Human CD56 | BD Biosciences | CAT#557747; clone: B159 |
| APC-Cy™7 Mouse Anti-Human CD16 | BD Biosciences | CAT#557758; clone: 3G8; RRID:AB_396853 |
| APC Mouse Anti-Human IFN-γ | BD Biosciences | CAT#554702; clone: B27; RRID:AB_398580 |
| PE MIP-1b Mouse anti-Human | BD Biosciences | CAT#550078; clone: D21-1351; RRID:AB_393549 |
| influenza A nucleoprotein-specific monoclonal antibody, clone A3 | Millipore | CAT# MAB8258; RRID:AB_95232 |
| influenza A nucleoprotein-specific monoclonal antibody , clone A1 | Millipore | Cat# MAB8257F-5; RRID:AB_570527 |
| anti-CD66b-Pacific blue | BioLegend | CAT#305112; clone: G10F5; RRID:AB_2563294 |
| Mouse Anti-Human IgG1-Fc PE | Southern Biotech | CAT # 9054-09; RRID:AB_2796628 |
| Mouse Anti-Human IgG2-Fc PE | Southern Biotech | CAT # 9060-09; RRID:AB_2796635 |
| Mouse Anti-Human IgG3-Hinge PE | Southern Biotech | CAT # 9210-09; RRID:AB_2796701 |
| Mouse Anti-Human IgG4-Fc PE | Southern Biotech | CAT # 9200-09; RRID:AB_2796693 |
| Mouse Anti-Human IgA1-Fc PE | Southern Biotech | CAT # 9130-09; RRID:AB_2796656 |
| Mouse Anti-Human IgA2-Fc PE | Southern Biotech | CAT # 9140-09; RRID:AB_2796664 |
| Mouse Anti-Human IgM-Fc PE | Southern Biotech | CAT # 9020-09; RRID:AB_2796577 |
| **Bacterial and virus strains** | | |
| H1N1 A/California/07/2009 | Produced in house | N.A. |
| H1N1 A/Michigan/45/2015 | Produced in house | N.A. |
| H3N2 A/Hong Kong/4801/2014 | Produced in house | N.A. |
| **Biological samples** | | |
| Cohort of pregnant/non-pregnant human serum samples | N.A. | N.A. |
| **Chemicals, peptides, and recombinant proteins** | | |
| G418 | ThermoFisher Scientific | CAT#10131027 |
| H3 HK HA | GeneScript | Custom made |
| chimeric HA bearing H1 A/Puerto Rico/8/1934 stalk (group 1) with mismatched H16 HA head | GeneScript | Custom made |
| chimeric HA bearing H3 HK stalk (group 2) with mismatched H4 HA head | GeneScript | Custom made |
| H1 M1 (HΔM H1N1 A/Michigan/45/2015) | Immune Technologies Corp. | CAT#: IT-003-00105ΔM |
| H1 CA (HΔTM A/California/07/2009) | Immune Technologies Corp. | CAT#: IT-003-00106ΔM |

(Continued on next page)
### REAGENT or RESOURCE SOURCE IDENTIFIER

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| H3 HK proteins (H3ÅTM H3N2 A/Hong Kong/4801/2014) | Immune Technologies Corp. | Cat: IT-003-004M24 |
| 1-Step Ultra TMB-ELISA substrate solution | ThermoFisher Scientific | CAT#34028 |
| receptor-destroying enzyme | Denka-Seiken | CAT#: 370013 |
| oseltamivir | selleckchem.com | CAT#: S2597 |
| veronal buffer supplemented with 0.1% fish skin gelatin | Boston Bio Products | CAT#: IBB-290X |

### Histopaque

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Human IL-15 Recombinant Protein, eBioscience | ThermoFisher Scientific | CAT#: BMS319 |
| Brefeldin A Solution | Biolegend | CAT#420601 |
| Golgistop, Protein transport inhibitor (Containing Monensin) | BD Biosciences | CAT#554724 |
| FIX&Perm Cell Permeabilization Kit | ThermoFisher Scientific | CAT#RGAS004 |
| EZ-Link NHS-LC-biotin | ThermoFisher Scientific | CAT#21343 |
| Bio-Glo luciferase assay reagent | Promega | CAT#: G7940 |
| BirA-500: BirA biotin-protein ligase standard reaction kit | Avidity | CAT#BirA500 |
| Streptavidin-R-Phycocerythrin | Prozyme | CAT#PJ31S |
| IDEZ-Protease | New England Biolabs | CAT#P0770S |
| GlycanAssure APTS kit | ThermoFisher Scientific | CAT#A28676 |
| RosetteSep™ Human NK Cell Enrichment Cocktail | Stem Cell Technologies | CAT#15065 |
| Human Fc receptors | Produced at the Duke Human Vaccine Institute, Boesch et al. 2014 | N/A |

### Experimental models: Cell lines

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| THP-1 Cells | ATCC | CAT#TIB-202 RRID: CVCL_0006 |
| Madin-Darby canine kidney-SIAT1 cells | Sigma Aldrich | CAT#R0571502 |
| Jurkat effector cells | Promega | CAT#: G7015 |

### Recombinant DNA

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| pFastBac gp67 vector | GenScript | GenScript propriety |

### Software and algorithms

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| ForeCyt software | | |
| GlycanAssure Software | ThermoFisher Scientific | https://www.thermofisher.com/us/en/home/life-sciences/bioproduction/contaminant-and-impurity-testing/glycanassure-glycan-analysis.html |
| GraphPad Prism | GraphPad | https://www.graphpad.com/scientific-software/prism/ |
| MATLAB | MathWorks | https://www.mathworks.com/products/matlab.html |

### Other

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| MaxiSorp microtiter plates | Thermo Fisher | CAT#: S0-112-3685 |
| Victor 3V multilabel reader | PerkinElmer | 1420 multilabel counter |
| FluoSpheres NeutrAvidin-Labeled Microspheres, 1.0 μm, red fluorescent (S05/S15), 1% solids | Invitrogen | CAT# F8775 |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Marcela Pasetti mpasetti@som.umaryland.edu

Materials availability
This study did not generate new unique reagents

Data and code availability
All data reported in this paper will be shared by the lead contact upon request. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL A AND SUBJECT DETAILS
Serum samples were obtained from pregnant (end of third trimester) and non-pregnant women, the majority of whom had received inactivated influenza vaccine during the 2017-2018 flu season; serum samples were obtained within 4 months of vaccination (Table S1, Figure S1). Pregnant women also received Tdap vaccine during pregnancy. Tdap and influenza vaccination occurred within 3-4 months interval for all participants except for three who had record of Tdap and influenza vaccine given the same day. The vaccine components for the northern hemisphere 2017-2018 season influenza vaccine included H1N1 A/Michigan/45/2015, H3N2 A/Hong Kong/4801/2014, B/Phuket/3073/2013, and B/Brisbane/60/2008-like viruses (WHO), 2017). All subjects were HIV, HBV, and HCV negative and provided written informed consent before enrollment. Human subject research was approved by the University of Maryland, Baltimore Institutional Review Board (HP-00065842 and HP-00040025) and by Partners Human Research Committee (Approval Number 2018P001060).

Cell lines
Madin-Darby canid kidney-SIAT1 cells (SIAT1-MDCK) were grown in Minimal Essential Media (MEM) plus 50 µg/ml of G418, 5% fetal bovine serum, 1X GlutaMAX™, and penicillin/streptomycin. Jurkat cells were cultured in 90% RPMI 1640 with l-glutamine and 10% FBS supplemented with 100 µg/ml hygromycin, 250 µg/ml Antibiotic G-418, 1 mM Sulfate Solution, 0.1 M sodium pyruvate, MEM and nonessential amino acids. THP-1 cells (ATCC, Manassas, VA, USA) were grown in R10 (RPMI plus 10% FBS L-glutamine and penicillin/streptomycin) supplemented with 0.01% β-mercaptoethanol.

Viruses
H1N1 A/California/07/2009 (H1 CA), H1N1 A/Michigan/45/2015 (H1 MI), and H3N2 A/Hong Kong/4801/2014 (H3 HK) were grown in 9-10 day old embryonated eggs. Infectious viral titer, i.e., 50% tissue culture
infectious dose (TCID50), was determined using a nucleoprotein-based enzyme-linked immunosorbent assay (ELISA) (Kosikova et al., 2018).

Recombinant proteins
For titer and avidity determination, genes coding H3 HK HA, chimeric HA bearing H1 A/Puerto Rico/8/1934 stalk (group 1) with mismatched H16 HA head and chimeric HA bearing H3 HK stalk (group 2) with mismatched H4 HA head were synthesized as previously described (Stevens et al., 2004; Pica et al., 2012; Radvak et al., 2021) and were subcloned into the pFastBac gp67 vector. Recombinant H3 HK HA, chimeric group 1 or group 2 stalk proteins expressed in Sf9 cells were column purified. For functional assays and Luminex Fc receptor binding and titer, recombinant H1 MI (HAΔM H1N1 A/Michigan/45/2015), H1 CA (HAΔTM A/California/07/2009) and H3 HK proteins (H3ΔTM H3N2 A/Hong Kong/4801/2014) expressed in 293 cells were used.

METHOD DETAILS

Anti-HA ELISA and avidity
HA-specific ELISA and avidity assays were performed as described (Kosikova et al., 2018). Briefly, serum samples were serially diluted and added to MaxiSorp microtiter plates coated with 0.2 μg/mL of recombinant protein. Plates were incubated at room temperature for 60 min. For avidity determination, antigen-antibody complexes were dissociated by incubation with 100 μl of 4 M urea for 15 min and plates blocked again for an additional hour (Kosikova et al., 2018). Bound antibodies were detected by addition of horseradish peroxidase-labeled goat anti-human IgG followed by 1-Step Ultra TMB substrate. Absorbance at 450 nm was measured in a Victor V multilabel reader. Antibody titers were determined by interpolation in a Sigmoidal four parameter logistic regression curve using Prism 9 (GraphPad, San Diego, CA), and avidity index was calculated based on the area under the curve (Kosikova et al., 2018).

Hemagglutination inhibition (HAI)
Sera were pre-treated with receptor-destroying enzyme (RDE), serially diluted two-fold (starting at 1:10) and incubated with 4 HA units per 25 μl of viruses at room temperature for 30 min. Hemagglutination was determined using 0.5% turkey red blood cells for H1N1 viruses or 0.75% guinea pig red blood cells in the presence of 20 nM oseltamivir for H3N2 viruses, respectively (Xie et al., 2011, 2015). HAI titers were reported as the reciprocal of the highest serum dilution that resulted in complete HAI. A titer of 5 was assigned if no inhibition was observed at the starting dilution.

Complement deposition
Antibody-dependent complement deposition (ADCD) was performed as previously described (Fischinger et al., 2019). Biotinylated recombinant HAΔM H1N1 A/Michigan/45/2015 and H3ΔTM H3N2 A/Hong Kong/4801/2014 were coupled to red fluorescent NeutrAvidin microspheres, incubated with sera and added to single wells as described above. Lyophilized guinea pig complement was resuspended in ice-cold water and diluted 1:100 in cold veronal buffer supplemented with 0.1% fish skin gelatin. 200 μl of diluted complement was added to each well, and plates were incubated for 20 min at 37°C, 5% CO₂. Plates were then washed twice with ice-cold 15 mM EDTA-PBS and stained with anti-guinea pig C3-FITC. After a final wash, beads were re-suspended in 50 μl of PBS and analyzed on the iQue Screener PLUS. Red-fluorescent beads were gated based on size. Complement deposition was determined as the geometric mean fluorescent intensity divided by 1,000. Data presented is area under the curve of the complement score averaged for two replicates.

NK cell activation
ELISA plates were coated with recombinant HAΔM H1N1 A/Michigan/45/2015 and H3ΔTM H3N2 A/Hong Kong/4801/2014 at 3 μg/mL of PBS for 2 h at 37°C, 5% CO₂. Plates were then washed three times with PBS and blocked overnight with 200 μl of 5% BSA in PBS. The next day, plates were washed, and samples were added in three serial dilutions (1:10, 1:50, 1:100) in a 50 μl volume and incubated 2 h at 37°C, 5% CO₂. NK cells were isolated from healthy adult PBMC using a RosetteSep NK Cell Enrichment Kit, according to manufacturer’s instructions, followed by density gradient centrifugation in Histopaque. A suspension of 1.5×10⁶ cells/ml in R10 was prepared, supplemented with 1 ng/ml rhIL15 and incubated overnight at 37°C, 5% CO₂. Prior to the assay, a suspension of 2.5×10⁶ cells/ml was prepared and 2.5 μg/ml of Brefeldin A and Golgistop and 2.5 μl of anti-CD107a were added. NK cells (5 × 10⁴ in 200 μl) were added to each well
containing Ag-Ab, and plates were incubated for 5 h at 37°C, 5% CO₂. Following the incubation and washing, cells were stained with anti-CD3, anti-CD56, and anti-CD16, washed, fixed, permeabilized with FIX&Perm kit, and stained intracellularly with anti-IFNγ and MIP-1β. Cells were resuspended in PBS and analyzed on the iQue Screener as described above. Influenza-specific IgG and PBS (diluent) were included as positive and negative controls. Negative control wells were used to set gates. Data were reported as the percentage of CD16⁺CD56⁺CD3⁻ NK cells positive for CD107a, IFNγ, or MIP-1β; reported values are the area under the curve of the mean of three replicates divided by 100,000.

**Microneutralization (MN)**

H1N1 and H3N2-specific MN titers were determined using a nucleoprotein-based ELISA as previously described (Kosikova et al., 2018). Briefly, RDE-treated sera were incubated with 100 50% tissue culture infectious dose (TCID₅₀) of virus for 1 h at room temperature, 5% CO₂, and then overlaid onto SIAT1-MDCK cells overnight. Infected cells were detected using influenza A nucleoprotein-specific monoclonal antibodies. MN titers were reported as the reciprocal of the highest serum dilution with ≥50% neutralization.

**Phagocytosis**

The antibody-dependent monocyte phagocytosis assay (ADCP) used was adapted from Ackerman et al. (2011) and the antibody-dependent neutrophil phagocytosis assay (ADNP) was performed as described (Karsten et al., 2019). Briefly, influenza antigens, recombinant HAΔM H1N1 A/Michigan/45/2015 and HAΔTM H3N2 A/Hong Kong/4801/2014 were biotinylated with a 20-fold excess of 10 mM EZ-Link NHS-LC-biotin and unbound biotin was removed using a Zeba Spin Desalting Column. Antigens were then mixed with yellow-green fluorescent NeutrAvidin microspheres at a ratio of 10 µl of beads per 10 µg of biotinylated protein and incubated at 37°C, 5% CO₂ for 2 h. Following incubation, beads were washed twice with PBS-0.01% BSA and resuspended in 1 mL of PBS-0.01% BSA. Serum samples were diluted 1:10, 1:50, and 1:100 in PBS, and 10 µl of each dilution was mixed with 10 µl of antigen-coupled fluorescent beads in a 96-well round bottom plate and incubated at 37°C, 5% CO₂ for 2 h. The beads were then washed with 200 µl of PBS. For the monocyte phagocytosis, THP-1 cells (2.5×10⁶ cells in 200 µl per well) were added to wells containing the beads, and plates were incubated for 16 h at 37°C, 5% CO₂. For the neutrophil phagocytosis, fresh neutrophils were isolated from whole blood of healthy adults and added (5×10⁵ cells in 200 µl) to bead-containing wells. Plates were incubated for 1 h at 37°C, 5% CO₂. Following incubation, cells were spun down and stained with anti-CD66b for 15 min. For both assays, cells were fixed with 100 µl of 4% paraformaldehyde (PFA) for 10 min, resuspended in 50 µl of PBS and analyzed by Flow cytometry using an iQue Screener PLUS and ForeCyt software. Influenza-specific IgG and PBS were included as positive and negative controls, respectively. Phagocytosis scores were calculated as the percentage of bead positive cells, multiplied by the geometric mean fluorescent intensity of the beads for bead positive cells, divided by 1×10⁷. All reported values are the area under the curve of the mean of two replicates.

**Cellular cytotoxicity**

Antibody-dependent cellular cytotoxicity (ADCC) assay was performed as previously described (Jacobsen et al., 2017) with modifications. Briefly, SIAT1-MDCK cells were seeded onto 96-well white flat-bottom plates (PerkinElmer), infected with H1 MI or H3 HK viruses, and incubated for 6 h at 37°C. RDE-treated sera (25 µl/well) and Jurkat effector cells (25 µl/well) were added to infected cells and incubated overnight at 37°C. Bio-Glo luciferase assay reagent was then added, and luminescence was measured using a Victor V multilabel reader.

**Antibody subclass and FcR binding**

IgG, IgA, IgM, and Fc receptor binding analyses were performed using a multiplex luminex assay as previously described (Brown et al., 2012). Briefly, recombinant HAΔM H1N1 A/Michigan/45/2015 and HAΔTM H3N2 A/Hong Kong/4801/2014 were coupled to MagPlex microspheres at a ratio of 25 µg of protein to 400 µl of beads. Microspheres were activated with 100 mM monobasic sodium phosphate pH 6.2 in the presence of 50 mg/ml EDC and 50 mg/ml sulfo-NHS, washed with 0.05 M 2[N-Morpholino]ethanesulfonic acid (MES) pH 5.0, incubated with antigen for 2 h at 37°C, 5% CO₂, and blocked with PBS-TBN (0.1% BSA, 0.02% tween-20, 0.05% Azide in PBS, pH 7.4) for 30 min. The beads were washed in PBS-0.05% tween-20, resuspended in 250 µl of PBS. Beads were added to 384-well plates and incubated
with sera at a final 1:500 dilution in luminex wash buffer (PBS-0.05% BSA-0.001% tween-20) for 2 h at room temperature and with shaking (800 rpm).

To detect antibody subclasses, following incubation, beads were washed in luminex buffer and incubated with PE-labeled anti-IgG, -IgG1, -IgG2, -IgG3, -IgG4, -IgA1, -IgA2, and -IgM for 1 h at room temperature with shaking. After washing, beads were resuspended in Qsol buffer and plates were read on an iQue Screener PLUS. H1N1 and H3N2 coupled beads were distinguished based on size and granularity, and data were analyzed as median fluorescent intensity of PE for each bead population.

To investigate Fc receptor binding, recombinant Fc receptors with an AviTag were biotinylated using a Bir500 kit according to manufacturer’s instructions and purified using a Zeba Spin Desalting Column. Biotin-labeled FcRs were then incubated with streptavidin-PE for 10 min and excess streptavidin was quenched with 20 μM biotin for another 10 min. Following bead and serum incubation, PE-Fc receptors were then added and incubated for a further 1 h at room temperature with shaking. Plates were then washed and analyzed on an iQue Screener as described above. Data reported for each sample represents the mean of two replicates.

**Glycosylation analysis**

Antigen-specific glycosylation analysis was performed as described in Jennewein et al., (2019). Briefly, recombinant HAΔM H1N1 A/Michigan/45/2015 and H3ΔTM H3N2 A/Hong Kong/4801/2014 were biotinylated and coupled to NeutrAvidin magnetic beads at a ratio of 2.5 μg of protein to 25 μl of beads. Sera (200 μl) were first incubated with non-coated NeutrAvidin beads to remove non-specific binding and then added to the antigen-coated beads and incubated for 1 h at 37°C. Antibodies were eluted by incubation in 50 μl of pH 2.9 citrate buffer for 30 min at 37°C. Samples were then spun down and the eluted antibodies, contained in the supernatant, were neutralized with 30 μl pH 8.9 potassium phosphate buffer. Antibodies were then coupled to protein G beads. After beads were washed, IDEZ was used to cleave the Fab (in the supernatant) from the Fc (remained on the magnetic beads) for 1 h at 37°C and collected. The two fragments were deglycosylated and fluorescently labeled using a GlycanAssure APTS kit according to manufacturer’s instructions. For the Fc fragment, which remained bound to the protein G beads, an additional magnetic separation after PNGase glycan cleavage separated the glycans from remaining magnetic beads and the protocol then proceeded per manufacturer’s instructions. Glycans were analyzed on a 3500xl genetic analyzer. Glycer fucosyl and afucosyl libraries were used to assign 24 discrete glycan peaks using GlycanAssure software. Data are reported as percentages of total glycans for each of the glycan peaks.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Mann-Whitney test (univariate analysis) was used to examine differences in readouts between pregnant and non-pregnant groups. p values are two-sided, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Data on radar plots were Z score normalized individually along each radar to an average of 0 with a standard deviation of 1. Multivariate Principal Component Analysis (PCA) and Least Absolute Shrinkage and Selection Operator (LASSO) and Partial Least Squares Discriminant Analysis (PLSDA, LASSO-PLSDA) were used to distinguish pregnant vs non-pregnant immune profiles. PCA was used to visualize whether pregnant and non-pregnant samples separate into discrete groups within the two-dimensional principal component (PC) space. LASSO-PLSDA was used to identify the features that were most important in separating the pregnant and non-pregnant samples (Lau et al., 2011; Arnold et al., 2016). LASSO is a regression analysis that selects a minimal set of variables that contribute to the differences between samples arranged along an ordinal dependent variable. It selects features that are required to create a maximum separation along a linear axis. These variables are then plotted and visualized on the PLSDA plot. Missing values were imputed using the k-nearest neighbor. Variables were centered and scaled to a standard deviation of 1. The LASSO-PLSDA model had a calibration success of 100% with a leave-1-out CV success of 97.0588%. Univariate and PCA analysis were performed with Prism 9 (GraphPad, San Diego, CA). MATLAB was used to perform PLSDA multivariate analysis.